Amylin (8-37), rat
规格
| Cas Number | 138398-61-5 |
| 规格或纯度 | ≥99% |
| 纯度 | ≥99% |
| 包装 | 1mg 或 5mg 或 500μg |
产品信息
| 品牌 | 阿拉丁 |
| 溶解性 | H2O : 50 mg/mL (15.62 mM; Need ultrasonic) |
| 过滤标签 | Amylin Receptor,GPCR/G Protein |
| 储存温度 | 干燥,-80℃储存 |
| 运输条件 | 超低温冰袋运输 |
| 生化和生理学机理 | 大鼠淀粉样蛋白（8-37）是原生淀粉样蛋白的截短类似物，可选择性地抑制肌肉组织中与胰岛素相关的葡萄糖摄取和糖原沉积。大鼠淀粉样蛋白（8-37）是一种弱淀粉样蛋白受体（AMY）拮抗剂。 |
| 英文描述 |
Amylin (8-37), rat is a truncated analog of native Amylin that selectively inhibits insulin-related glucose uptake and glycogen deposition in muscle tissue. Amylin (8-37), rat is a weak amylin receptor ( AMY ) antagonist. In Vitro Amylin (8-37), rat (Rat amylin-(8-37)) enhances insulin action and alters lipid metabolism in normal and insulin-resistant rats. Amylin (8-37) reduces plasma insulin (P<0.001) and enhances several measures of whole body and muscle insulin sensitivity (P<0.05) in both saline- and hGH-infused rats. Amylin-(8-37) corrects hGH-induced liver insulin resistance, increases basal plasma triglycerides and lowers plasma nonesterified fatty acids in both groups, and reduces muscle triglyceride and total long-chain acyl-CoA content in saline-treated rats (P<0.05). In isolated soleus muscle, Amylin (8-37) blocks amylin-induced inhibition of glycogen synthesis but has no effect in the absence of amylin. Thus 1) hyperamylinemia accompanies insulin resistance induced by hGH infusion; 2) Amylin (8-37) increases whole body and muscle insulin sensitivity and consistently reduces basal insulin levels in normal and hGH-induced insulin resistant rats; and 3) Amylin (8-37) elicits a significant alteration of in vivo lipid metabolism. MCE has not independently confirmed the accuracy of these methods. They are for reference only. Form:Solid IC50& Target:Amylin receptor (AMY) |